Comparison on efficacy and safety of TACE combined with 125I seeds implantation or lenvatinib for treating hepatocellular carcinoma complicated with portal vein tumor thrombosis
10.13929/j.issn.1672-8475.2023.12.003
- VernacularTitle:对比TACE联合125I粒子与联合仑伐替尼治疗肝细胞癌伴门静脉癌栓的有效性及安全性
- Author:
Weiwei SUN
1
;
Wei LI
;
Wenling MAN
;
Chang DONG
;
Po YANG
Author Information
1. 哈尔滨医科大学附属第四医院介入血管外科,黑龙江 哈尔滨 150001
- Keywords:
carcinoma,hepatocellular;
portal vein cancer thrombus;
chemoembolization,therapeutic;
iodine isotopes
- From:
Chinese Journal of Interventional Imaging and Therapy
2023;20(12):713-717
- CountryChina
- Language:Chinese
-
Abstract:
Objective To comparatively observe the efficacy and safety of TACE combined with 125I seeds implantation or lenvatinib for treating hepatocellular carcinoma(HCC)complicated with portal vein tumor thrombosis(PVTT).Methods Totally 52 HCC patients complicated with type Ⅱ or type Ⅲ PVTT were enrolled and divided into TACE combined with 125I seeds group(group A,n=27)and TACE combined with lenvatinib group(group B,n=25).Objective response rate(ORR),overall survival(OS)and incidence rate of adverse reaction were compared between groups.Results ORR,the median OS,median OS of type Ⅱ PVTT and median OS of type Ⅲ PVTT was 70.37%(19/27),13.6 months,14.1 months and 13.2 months in group A,and 32.00%(8/25),11.3 months,12.3 months and 10.4 months in group B,respectively.The above indexes in group A were all better than those in group B(all P＜0.05).In group A,the incidence rate of adverse reaction was 48.15%(13/27),and no serious complication occurred.In group B,the incidence rate of adverse reaction was 88.00%(22/25),and severe drug toxicity was noticed in 5 cases(5/25,20.00%).Conclusion The efficacy and safety of TACE combined with 125I seeds were both better than those of TACE combined with lenvatinib for treating HCC complicated with PVTT.
